<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Med. Genet</journal-id>
      <journal-title-group>
        <journal-title>BMC Medical Genetics</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2350</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24373500</article-id>
      <article-id pub-id-type="pmc">3913615</article-id>
      <article-id pub-id-type="publisher-id">1471-2350-14-129</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2350-14-129</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Multiplex genetic cancer testing identifies pathogenic mutations in <italic>TP53</italic> and <italic>CDH1</italic> in a patient with bilateral breast and endometrial adenocarcinoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Heitzer</surname>
            <given-names>Ellen</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>ellen.heitzer@medunigraz.at</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Lax</surname>
            <given-names>Sigurd</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>Sigurd.LAX@lkh-grazwest.at</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Lafer</surname>
            <given-names>Ingrid</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>ingrid.lafer@medunigraz.at</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>M&#xFC;ller</surname>
            <given-names>Stephanie M</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>st.mueller@medunigraz.at</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Pristauz</surname>
            <given-names>Gunda</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>gunda.pristauz@klinikum-graz.at</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Ulz</surname>
            <given-names>Peter</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>peter.ulz@medunigraz.at</email>
        </contrib>
        <contrib contrib-type="author" id="A7">
          <name>
            <surname>Jahn</surname>
            <given-names>Stephan</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>stephan.jahn@medunigraz.at</email>
        </contrib>
        <contrib contrib-type="author" id="A8">
          <name>
            <surname>H&#xF6;genauer</surname>
            <given-names>Christoph</given-names>
          </name>
          <xref ref-type="aff" rid="I5">5</xref>
          <email>christoph.hoegenauer@medunigraz.at</email>
        </contrib>
        <contrib contrib-type="author" id="A9">
          <name>
            <surname>Petru</surname>
            <given-names>Edgar</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>edgar.petru@medunigraz.at</email>
        </contrib>
        <contrib contrib-type="author" id="A10">
          <name>
            <surname>Speicher</surname>
            <given-names>Michael R</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>michael.speicher@medunigraz.at</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A11">
          <name>
            <surname>Geigl</surname>
            <given-names>Jochen B</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>jochen.geigl@medunigraz.at</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Institute of Human Genetics, Medical University of Graz, Harrachgasse 21/8, A-8010 Graz, Austria</aff>
      <aff id="I2"><label>2</label>Department of Pathology, General Hospital Graz West, Goestingerstrasse 22, A-8020 Graz, Austria</aff>
      <aff id="I3"><label>3</label>Department of Obstetrics and Gynecology, Medical University of Graz, Auenbruggerplatz 14, A-8036 Graz, Austria</aff>
      <aff id="I4"><label>4</label>Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria</aff>
      <aff id="I5"><label>5</label>Division of Gastroenterology and Hepatology, Medical University of Graz, Auenbruggerplatz 15, A-8036 Graz, Austria</aff>
      <pub-date pub-type="collection">
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>29</day>
        <month>12</month>
        <year>2013</year>
      </pub-date>
      <volume>14</volume>
      <fpage>129</fpage>
      <lpage>129</lpage>
      <history>
        <date date-type="received">
          <day>12</day>
          <month>9</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>12</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2013 Heitzer et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder>Heitzer et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-2350/14/129"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Germline genetic testing for familial cancer syndromes is usually performed serially for the most likely genetic causes. In recent years the way genetic testing carried out has changed, as next generation sequencing now allows the simultaneous testing of multiple susceptibility genes at low costs.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>Here, we present a female with bilateral breast cancer and endometrial adenocarcinoma. After simultaneous sequencing of 150 genes (890&#xA0;kb) associated with hereditary cancer we identified pathogenic mutations in two high-penetrance genes, i.e. <italic>TP53</italic> and <italic>CDH1</italic> that would most likely not have been elucidated by serial screening of candidate genes.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>As the two mutated genes are located on different chromosomes and cause different cancer syndromes these findings had a tremendous impact not only on genetic counseling of the index patient and her family but also on subsequent surveillance strategies.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Multiplex genetic testing</kwd>
        <kwd>Cancer susceptibility</kwd>
        <kwd>TP53</kwd>
        <kwd>CDH1</kwd>
        <kwd>Next generation sequencing</kwd>
        <kwd>NGS</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Testing for mutations in high-penetrance cancer predisposition genes, such as <italic>BRCA1</italic> or <italic>BRCA2</italic>, has evolved to an integral part of cancer care because it provides clear information to patients and their families and established guidelines for surveillance with proven benefit exist (<ext-link ext-link-type="uri" xlink:href="http://www.nccn.org">http://www.nccn.org</ext-link>). Germline genetic testing is usually performed serially for the most likely genetic causes [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. As the genetic architecture of cancer predisposition is often complex, genetic testing panels using next-generation sequencing for hereditary cancers have recently been introduced [<xref ref-type="bibr" rid="B3">3</xref>]. Here, we present a female with bilateral breast cancer and endometrial adenocarcinoma, where multiplex genetic testing revealed pathogenic mutations in two high-penetrance genes, i.e. <italic>TP53</italic> and <italic>CDH1</italic>. We describe why traditional serial genetic testing would most likely not have elucidated both mutations, which had a tremendous impact on the index patient and her family.</p>
    </sec>
    <sec sec-type="methods">
      <title>Methods</title>
      <p>The patient and her family received genetic counseling and written informed consent was obtained. BRCA mutation testing using genomic DNA extracted from peripheral blood leukocytes (PBL) was performed. As no mutation was identified, the index patient was included in a study to evaluate a multiplex genetic testing panel for individuals with cancer.</p>
      <p>To this end a total of 150 genes corresponding to 890&#xA0;kb (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Figure S1), which are associated with hereditary cancer or with frequent somatic mutations according to the COSMIC (<ext-link ext-link-type="uri" xlink:href="http://www.sanger.ac.uk/genetics/CGP/cosmic/">http://www.sanger.ac.uk/genetics/CGP/cosmic/</ext-link>) and Cancer Gene Census (<ext-link ext-link-type="uri" xlink:href="http://www.sanger.ac.uk/genetics/CGP/Census/">http://www.sanger.ac.uk/genetics/CGP/Census/</ext-link>) were enriched using a SeqCap EZ Choice Library (Roche Nimblegen, Madison, WI, USA), following the manufacturer&#x2019;s instructions. Sequencing was performed on the Roche 454FLX platform using the Lib-L protocol (emPCR Method Manual &#x2013; Lib-L LV).</p>
      <p>For cDNA analyses we transcribed leukocyte derived mRNA into cDNA.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>The index patient was a 46-year old female (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>; III-3) of Afghan origin. At 38&#xA0;years of age she was diagnosed with a left sided ductal-invasive breast cancer. At 43&#xA0;years of age a FIGO Ia endometrial adenocarcinoma was diagnosed, one year later a contralateral, i.e. right sided, invasive breast cancer was detected. She had 4 daughters and two sons (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>; IV-1 to IV-6). One of the sons (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>; IV-1) died from a brain tumor at the age of 17&#xA0;years. The other children (IV-2 to IV-6) were healthy.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Pedigree of a family with mutations in both </bold><bold><italic>TP53 </italic></bold><bold>and </bold><bold><italic>CDH1 </italic></bold><bold>showing inheritance of different types of tumors.</bold> Cancer types are marked in different colours. Age in years [y] at diagnosis or current age is indicated below the symbols. Blue arrow indicates the index patient.</p>
        </caption>
        <graphic xlink:href="1471-2350-14-129-1"/>
      </fig>
      <p>One sister (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>; III-1) of our index patient died at the age of 28&#xA0;years of breast cancer, diagnosed at 26&#xA0;years of age, whereas two other siblings (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>; III-2, III-4) were healthy. The mother of our index patient died at the age of 53&#xA0;years of a myocardial infarction (not shown in the pedigree). On the maternal side there were no cases of known malignant diseases. The family members from the paternal side were all diagnosed and treated in Afghanistan and we were not able to retrieve written documentation. According to the relatives, the father (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>; II-1) died with 63&#xA0;years of age of gastric cancer. His uncle (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>; I-2) was also diagnosed with gastric cancer at &#x201C;high age&#x201D; (&gt;80&#xA0;years), the son (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>; II-2) of this uncle died of an unknown malignant disease and his two grand-daughters (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>; III-5, III-6) both died at young ages of breast cancer.</p>
      <p>The history allowed the differential diagnosis of three autosomal dominantly inherited cancer predisposition syndromes. First, the familial breast-ovarian cancer either due to heterozygous germline mutations in <italic>BRCA1</italic> (OMIM #604370) or <italic>BRCA2</italic> (OMIM #612555), because the index patient and her sister had early-age-onset (&#x2264;50&#xA0;years) breast cancer and the index patient bilateral disease [<xref ref-type="bibr" rid="B4">4</xref>]. Second, Li-Fraumeni syndrome (LFS, OMIM #151623) caused by germline mutations of <italic>TP53</italic>, which presents with a variety of tumor types, most notably sarcomas, breast cancer, adrenal cortical carcinoma, and brain tumors [<xref ref-type="bibr" rid="B5">5</xref>]. Breast cancer is the most common tumor in women with LFS [<xref ref-type="bibr" rid="B6">6</xref>]. <italic>TP53</italic> genetic testing could have been considered according to the Chompret criteria [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>] because both the index patient and one first-degree relative, i.e. her son, had cancers from the LFS tumor spectrum (breast, brain) before 46&#xA0;years of age. Third, hereditary diffuse gastric cancer (HDGC, OMIM #137215) characterized by diffuse-type gastric cancer and an elevated risk of lobular breast cancer, which is caused by germline mutations of <italic>CDH1</italic> coding for E-cadherin [<xref ref-type="bibr" rid="B9">9</xref>]. However, the current criteria for <italic>CDH1</italic> genetic testing [<xref ref-type="bibr" rid="B10">10</xref>] require histopathological confirmation of diffuse gastric cancer in at least one family member, which we did not have, and both gastric cancer cases were not diagnosed below the age of 50&#xA0;years.</p>
      <p>As families who have a predominance of premenopausal breast cancer are more likely to have mutations in <italic>BRCA1</italic> or <italic>BRCA2</italic> than in <italic>TP53</italic>[<xref ref-type="bibr" rid="B11">11</xref>], we started our diagnostic work-up with Sanger sequencing and MLPA (Multiplex Ligation-dependent Probe Amplification) of the two breast cancer genes. However, this did not reveal disease-associated mutations.</p>
      <p>We next offered the index patient participation in a study with the aim to evaluate a multiplex genetic testing panel for individuals with cancer. This study was approved by the Ethics Committee of the Medical University of Graz. After extensive counseling and obtaining of a written informed consent, we performed targeted resequencing of 150 genes (890&#xA0;kb) associated with hereditary cancer or with frequent somatic mutations according to the COSMIC (<ext-link ext-link-type="uri" xlink:href="http://www.sanger.ac.uk/genetics/CGP/cosmic/">http://www.sanger.ac.uk/genetics/CGP/cosmic/</ext-link>) and Cancer Gene Census (<ext-link ext-link-type="uri" xlink:href="http://www.sanger.ac.uk/genetics/CGP/Census/">http://www.sanger.ac.uk/genetics/CGP/Census/</ext-link>) databases. SNV calling identified a total of 446 variants. These variants were filtered first for the non-synonymous, splice acceptor-site and donor-site and insertions/deletions mutation and then against available public databases (dbSNP132, 1000 Genome variants databases). After this variant prioritization we identified heterozygous germline mutations in two high-penetrance genes, i.e. <italic>TP53</italic> (c.673-1&#xA0;G&#x2009;&gt;&#x2009;A) and <italic>CDH1</italic> (c.892&#xA0;G&#x2009;&gt;&#x2009;A, p.A298T), and one mutation in <italic>NUP214</italic> (c.2160A&#x2009;&gt;&#x2009;C, p.L720F) which we confirmed by Sanger sequencing (Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>: Table S1). The <italic>CDH1</italic> mutation was previously reported in a family with three affected members with diffuse gastric cancer. The mutation dramatically decreases the ability of E-cadherin to mediate cell-cell adhesion and to suppress cell invasion and is therefore listed as causative in HGMD [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. The <italic>TP53</italic> mutation had also been previously observed in a LFS family and analysis of the cDNA had demonstrated that this mutation resulted in a variant transcript [<xref ref-type="bibr" rid="B14">14</xref>]. We had only leukocyte derived mRNAs available to confirm this; however, no splice variants were detected in the respective cDNAs. Similar observations with leukocyte derived mRNAs were previously reported for other <italic>TP53</italic> splice site mutations [<xref ref-type="bibr" rid="B15">15</xref>] and indicate most likely that the resulting transcripts were unstable and subsequently degraded. As we could not repeat these experiments with an immortalized cell line we carefully analyzed available tumor material from our index patient with immunohistochemistry as outlined below. The <italic>NUP214</italic> mutation was not previously reported. To explore the significance of these mutations further, we analyzed them using various prediction programs including SIFT, PolyPhen, and LRT. As expected for the two previously reported pathogenic mutations in <italic>CDH1</italic> and <italic>TP53</italic> these prediction programs indicated structurally damaging effects. In contrast, these programs suggested for the <italic>NUP214</italic> mutation a non-pathogenic effect. Somatic <italic>NUP214</italic> mutations were mainly reported in cervix and endometrium carcinoma (<ext-link ext-link-type="uri" xlink:href="http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NUP214#dist">http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NUP214#dist</ext-link>), whereas germline <italic>NUP214</italic> were to best of our knowledge never reported. Altogether this suggests that the <italic>NUP214</italic> mutation does not contribute to the tumor spectrum in our patient.</p>
      <p>Histology of the left-sided breast carcinoma was not available, since surgery had been performed in Pakistan. All sections of the right-sided breast carcinoma were reviewed and histologically revealed an invasive carcinoma of no special type, grade 2, with focal lobular features (mixed invasive carcinoma) and an associated minor grade 2 intraductal component (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>A). The lobular component was composed of small cells with monomorphic nuclei, arranged in single cell files (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>B). Immunohistochemistry showed membrane staining for E-cadherin, which was less intense within the component with lobular features (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>C-D). TP53 expression was absent in both the invasive and the intraductal carcinoma (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>E-F), indicating that the spliced mutant protein is not expressed. The endometrial adenocarcinoma was of endometrioid type with secretory changes and showed immunoreactivity for E-cadherin, but a flat negative immunoreactive pattern for TP53.</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>H&amp; E- and immunostaining of p53 and E-cadherin proteins in different tumor sections. A)</bold> H&amp;E staining of the right-sided breast carcinoma showing an invasive carcinoma, grade 2, with focal lobular features. <bold>B)</bold> H&amp; E staining of the right-sided breast carcinoma showing the lobular component. <bold>C,</bold><bold>D)</bold> Immunostaining for E-cadherin. Positive cells (brownish) are present at the membrane but in a clearly lower portion within the component with lobular features. <bold>E,</bold><bold>F)</bold> Immunostaining for p53 was negative for both, the invasive and the intraductal carcinoma.</p>
        </caption>
        <graphic xlink:href="1471-2350-14-129-2"/>
      </fig>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>Our case represents a diagnostic challenge: In the family several different organs are involved, i.e. breast, stomach, uterus, and brain (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>). As several family members were diagnosed and treated abroad, written documentation was incomplete. With traditional serial genetic diagnostics, <italic>TP53</italic> testing would have been the most likely next step after <italic>BRCA1</italic>/<italic>BRCA2</italic> sequencing. Although an uncommon manifestation of LFS, gastric cancer has been suggested to be a component of the LFS tumor spectrum [<xref ref-type="bibr" rid="B16">16</xref>] so that all tumors in this family could have been attributed to the <italic>TP53</italic> germline mutation without apparent need for further sequencing of other genes. However, the correct identification of germline mutations is important because LFS and HDGC require intensive and different clinical management.</p>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p><bold>Different organs are affected with cancer in one family.</bold> Left: tumors observed in males; right: tumors in females; the most likely causative gene is indicated for each tumor.</p>
        </caption>
        <graphic xlink:href="1471-2350-14-129-3"/>
      </fig>
      <p>The lifetime risk of developing cancer is estimated at be as high as 73% for male and 93% for female germline <italic>TP53</italic> mutation carriers [<xref ref-type="bibr" rid="B17">17</xref>]. While in the past LFS screening programs often lacked effectiveness a recent novel surveillance protocol using non-invasive biochemical and imaging modalities enabled the presymptomatic detection of malignancies in <italic>TP53</italic> mutation carriers and prolonged survival [<xref ref-type="bibr" rid="B18">18</xref>]. Such a surveillance strategy offers new management options and may change attitudes towards genetic <italic>TP53</italic> screening.</p>
      <p>Carriers of <italic>CDH1</italic> germline mutations have a cumulative gastric cancer risk, before age 75, of 40&#x2013;67% for men and 63&#x2013;83% for women and a risk for lobular breast cancer of 39&#x2013;52% [<xref ref-type="bibr" rid="B19">19</xref>]. Total prophylactic gastrectomy is the only reliable intervention for carriers of pathogenic mutations [<xref ref-type="bibr" rid="B9">9</xref>] and was discussed with our patient, illustrating how multiplex genetic testing can change clinical management.</p>
      <p>Furthermore, this situation presents a challenge for genetic counseling as the two mutated genes are located on different chromosomes, i.e. <italic>CDH1</italic> on chromosome 16q22.1 and <italic>TP53</italic> on 17p13.1. Each mutation is inherited with a 50% chance. There is only a 25% probability that a child will inherit no mutation, a 50% chance to inherit one of the two mutated genes and a 25% chance to inherit both (Figure&#xA0;<xref ref-type="fig" rid="F4">4</xref>). It is very likely that the son, who died at 17&#xA0;years of age (IV-1 in Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>) had at least inherited the mutated <italic>TP53</italic>, as LFS-related brain tumors can occur in either childhood or adulthood with a median age of onset of 16&#xA0;years [<xref ref-type="bibr" rid="B6">6</xref>]. The 28 and 25&#xA0;year old daughters (IV-2, IV-3) live in Afghanistan and were not available for genetic testing. We identified the <italic>CDH1</italic> but not the <italic>TP53</italic> mutation in the second son (IV-4), whereas no mutation was found in the two younger daughters (IV-5, IV-6).</p>
      <fig id="F4" position="float">
        <label>Figure 4</label>
        <caption>
          <p><bold>Possible segregation patterns of the two mutated genes that are located on different chromosomes.</bold> red: maternal; blue: paternal chromosomes.</p>
        </caption>
        <graphic xlink:href="1471-2350-14-129-4"/>
      </fig>
      <p>In summary, we demonstrate a case, where multiplex genetic testing enabled us to establish a diagnosis, which would likely have been missed with serial testing. However, the increased risk for detection of variants of unknown significance represents a concern of multiplex genetic panels [<xref ref-type="bibr" rid="B3">3</xref>]. An example is the <italic>NUP214</italic> mutation, which we observed in the index patient and which very likely did not increase tumor susceptibility. To address this issue we now designed gene panels that only include high penetrance gene with clear implications to hereditary tumor syndromes. The growing awareness about the importance of identifying mutation carriers was recently reflected in recommendations released by the American College of Medical Genetics and Genomics [<xref ref-type="bibr" rid="B20">20</xref>]. These guidelines state that anyone whose genome is sequenced for any medical reason should automatically learn -without further consent- about mutations in the cancer-predisposition genes for which risk reducing or live saving measures exist. This proposed shift in handling genetic data and the complexity of hereditary multigene cancer panels as illustrated in this report represent novel challenges for cancer genetics professionals.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors indicated no potential conflicts of interest.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>EH: Project planning and experimental design. Sequencing, next-generation sequencing and data analysis and drafted the manuscript. Manuscript writing, SL: Review of histology IL: Review of clinical data. GP: Review of clinical data. PU: Sequencing, next-generation sequencing and data analysis. SJ: Review of histology. CH: Review of clinical data. EP: Review of clinical data. MRS: Project planning and experimental design, Manuscript writing. JBG: Project planning and experimental designs Review of clinical data, Manuscript writing. All authors read and approved the final manuscript.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/14/129/prepub">http://www.biomedcentral.com/1471-2350/14/129/prepub</ext-link>
      </p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="S1">
        <caption>
          <title>Additional file 1: Figure S1</title>
          <p>Electropherogramm and IGV alignment showing mutations in TP53 and CDH1.</p>
        </caption>
        <media xlink:href="1471-2350-14-129-S1.tiff">
          <caption>
            <p>Click here for file</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S2">
        <caption>
          <title>Additional file 2: Table S1</title>
          <p>List of genes that were enriched for sequencing.</p>
        </caption>
        <media xlink:href="1471-2350-14-129-S2.xlsx">
          <caption>
            <p>Click here for file</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>Funding was provided by the F&#xF6;rderung durch die Steierm&#xE4;rkische Landesregierung GZ: A3-16.M-94/2009-14.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Weitzel</surname>
            <given-names>JN</given-names>
          </name>
          <name>
            <surname>Blazer</surname>
            <given-names>KR</given-names>
          </name>
          <name>
            <surname>Macdonald</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Culver</surname>
            <given-names>JO</given-names>
          </name>
          <name>
            <surname>Offit</surname>
            <given-names>K</given-names>
          </name>
          <article-title>Genetics, genomics, and cancer risk assessment: state of the art and future directions in the Era of personalized medicine</article-title>
          <source>CA Cancer J Clin</source>
          <year>2011</year>
          <volume>14</volume>
          <fpage>327</fpage>
          <lpage>359</lpage>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Speicher</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Geigl</surname>
            <given-names>JB</given-names>
          </name>
          <name>
            <surname>Tomlinson</surname>
            <given-names>IP</given-names>
          </name>
          <article-title>Effect of genome-wide association studies, direct-to-consumer genetic testing, and high-speed sequencing technologies on predictive genetic counselling for cancer risk</article-title>
          <source>Lancet Oncol</source>
          <year>2010</year>
          <volume>14</volume>
          <fpage>890</fpage>
          <lpage>898</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(09)70359-6</pub-id>
          <pub-id pub-id-type="pmid">20537948</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Domchek</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Bradbury</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Garber</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Offit</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Robson</surname>
            <given-names>ME</given-names>
          </name>
          <article-title>Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?</article-title>
          <source>J Clin Oncol</source>
          <year>2013</year>
          <volume>14</volume>
          <fpage>1267</fpage>
          <lpage>1270</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2012.46.9403</pub-id>
          <pub-id pub-id-type="pmid">23460708</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Shannon</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Chittenden</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Genetic testing by cancer site: breast</article-title>
          <source>Cancer J</source>
          <year>2012</year>
          <volume>14</volume>
          <fpage>310</fpage>
          <lpage>319</lpage>
          <pub-id pub-id-type="doi">10.1097/PPO.0b013e318260946f</pub-id>
          <pub-id pub-id-type="pmid">22846731</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mai</surname>
            <given-names>PL</given-names>
          </name>
          <name>
            <surname>Malkin</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Garber</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Schiffman</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Weitzel</surname>
            <given-names>JN</given-names>
          </name>
          <name>
            <surname>Strong</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Wyss</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Locke</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Means</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Achatz</surname>
            <given-names>MI</given-names>
          </name>
          <name>
            <surname>Hainaut</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Frebourg</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Evans</surname>
            <given-names>DG</given-names>
          </name>
          <name>
            <surname>Bleiker</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Patenaude</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Schneider</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Wilfond</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Peters</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Hwang</surname>
            <given-names>PM</given-names>
          </name>
          <name>
            <surname>Ford</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Tabori</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Ognjanovic</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Dennis</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Wentzensen</surname>
            <given-names>IM</given-names>
          </name>
          <name>
            <surname>Greene</surname>
            <given-names>MH</given-names>
          </name>
          <name>
            <surname>Fraumeni</surname>
            <given-names>JF</given-names>
            <suffix>Jr</suffix>
          </name>
          <name>
            <surname>Savage</surname>
            <given-names>SA</given-names>
          </name>
          <article-title>Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium</article-title>
          <source>Cancer Gene</source>
          <year>2012</year>
          <volume>14</volume>
          <fpage>479</fpage>
          <lpage>487</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cancergen.2012.06.008</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Olivier</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Goldgar</surname>
            <given-names>DE</given-names>
          </name>
          <name>
            <surname>Sodha</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Ohgaki</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kleihues</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Hainaut</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Eeles</surname>
            <given-names>RA</given-names>
          </name>
          <article-title>Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype</article-title>
          <source>Cancer Res</source>
          <year>2003</year>
          <volume>14</volume>
          <fpage>6643</fpage>
          <lpage>6650</lpage>
          <pub-id pub-id-type="pmid">14583457</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Chompret</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Abel</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Stoppa-Lyonnet</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Brugieres</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Pages</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Feunteun</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Bonaiti-Pellie</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Sensitivity and predictive value of criteria for p53 germline mutation screening</article-title>
          <source>J Med Genet</source>
          <year>2001</year>
          <volume>14</volume>
          <fpage>43</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="doi">10.1136/jmg.38.1.43</pub-id>
          <pub-id pub-id-type="pmid">11332399</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Tinat</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Bougeard</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Baert-Desurmont</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Vasseur</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Martin</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Bouvignies</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Caron</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Bressac-de Paillerets</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Berthet</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Dugast</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Bonaiti-Pellie</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Stoppa-Lyonnet</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Frebourg</surname>
            <given-names>T</given-names>
          </name>
          <article-title>2009 version of the Chompret criteria for Li Fraumeni syndrome</article-title>
          <source>J Clin Oncol</source>
          <year>2009</year>
          <volume>14</volume>
          <fpage>e108</fpage>
          <lpage>109</lpage>
          <comment>author reply e110</comment>
          <pub-id pub-id-type="doi">10.1200/JCO.2009.22.7967</pub-id>
          <pub-id pub-id-type="pmid">19652052</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Oliveira</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Pinheiro</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Figueiredo</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Seruca</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Carneiro</surname>
            <given-names>F</given-names>
          </name>
          <article-title>E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer</article-title>
          <source>Prog Mol Biol Transl Sci</source>
          <year>2013</year>
          <volume>14</volume>
          <fpage>337</fpage>
          <lpage>359</lpage>
          <pub-id pub-id-type="pmid">23481202</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Fitzgerald</surname>
            <given-names>RC</given-names>
          </name>
          <name>
            <surname>Hardwick</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Huntsman</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Carneiro</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Guilford</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Blair</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Chung</surname>
            <given-names>DC</given-names>
          </name>
          <name>
            <surname>Norton</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Ragunath</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Van Krieken</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Dwerryhouse</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Caldas</surname>
            <given-names>C</given-names>
          </name>
          <article-title>International gastric cancer linkage C: hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research</article-title>
          <source>J Med Genet</source>
          <year>2010</year>
          <volume>14</volume>
          <fpage>436</fpage>
          <lpage>444</lpage>
          <pub-id pub-id-type="doi">10.1136/jmg.2009.074237</pub-id>
          <pub-id pub-id-type="pmid">20591882</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Walsh</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Casadei</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Coats</surname>
            <given-names>KH</given-names>
          </name>
          <name>
            <surname>Swisher</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Stray</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Higgins</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Roach</surname>
            <given-names>KC</given-names>
          </name>
          <name>
            <surname>Mandell</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>MK</given-names>
          </name>
          <name>
            <surname>Ciernikova</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Foretova</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Soucek</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>King</surname>
            <given-names>MC</given-names>
          </name>
          <article-title>Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer</article-title>
          <source>JAMA</source>
          <year>2006</year>
          <volume>14</volume>
          <fpage>1379</fpage>
          <lpage>1388</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.295.12.1379</pub-id>
          <pub-id pub-id-type="pmid">16551709</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Brooks-Wilson</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Kaurah</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Suriano</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Leach</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Senz</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Grehan</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Butterfield</surname>
            <given-names>YS</given-names>
          </name>
          <name>
            <surname>Jeyes</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Schinas</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Bacani</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kelsey</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ferreira</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>MacGillivray</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>MacLeod</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Micek</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ford</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Foulkes</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Australie</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Greenberg</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>LaPointe</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Gilpin</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Nikkel</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Gilchrist</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Hughes</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Jackson</surname>
            <given-names>CE</given-names>
          </name>
          <name>
            <surname>Monaghan</surname>
            <given-names>KG</given-names>
          </name>
          <name>
            <surname>Oliveira</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Seruca</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Gallinger</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Caldas</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
          <article-title>Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria</article-title>
          <source>J Med Genet</source>
          <year>2004</year>
          <volume>14</volume>
          <fpage>508</fpage>
          <lpage>517</lpage>
          <pub-id pub-id-type="doi">10.1136/jmg.2004.018275</pub-id>
          <pub-id pub-id-type="pmid">15235021</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mateus</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Simoes-Correia</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Figueiredo</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Heindl</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Alves</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Suriano</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Luber</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Seruca</surname>
            <given-names>R</given-names>
          </name>
          <article-title>E-cadherin mutations and cell motility: a genotype-phenotype correlation</article-title>
          <source>Exp Cell Res</source>
          <year>2009</year>
          <volume>14</volume>
          <fpage>1393</fpage>
          <lpage>1402</lpage>
          <pub-id pub-id-type="doi">10.1016/j.yexcr.2009.02.020</pub-id>
          <pub-id pub-id-type="pmid">19268661</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bougeard</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Limacher</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Martin</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Charbonnier</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Killian</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Delattre</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Longy</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Jonveaux</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Fricker</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Stoppa-Lyonnet</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Flaman</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Frebourg</surname>
            <given-names>T</given-names>
          </name>
          <article-title>Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome</article-title>
          <source>J Med Genet</source>
          <year>2001</year>
          <volume>14</volume>
          <fpage>253</fpage>
          <lpage>257</lpage>
          <pub-id pub-id-type="doi">10.1136/jmg.38.4.253</pub-id>
          <pub-id pub-id-type="pmid">11370630</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Verselis</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Rheinwald</surname>
            <given-names>JG</given-names>
          </name>
          <name>
            <surname>Fraumeni</surname>
            <given-names>JF</given-names>
            <suffix>Jr</suffix>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>FP</given-names>
          </name>
          <article-title>Novel p53 splice site mutations in three families with Li-Fraumeni syndrome</article-title>
          <source>Oncogene</source>
          <year>2000</year>
          <volume>14</volume>
          <fpage>4230</fpage>
          <lpage>4235</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.onc.1203758</pub-id>
          <pub-id pub-id-type="pmid">10980596</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Masciari</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Dewanwala</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Stoffel</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Lauwers</surname>
            <given-names>GY</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Achatz</surname>
            <given-names>MI</given-names>
          </name>
          <name>
            <surname>Riegert-Johnson</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Foretova</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Silva</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Digianni</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Verselis</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Schneider</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>FP</given-names>
          </name>
          <name>
            <surname>Fraumeni</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Garber</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Syngal</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Gastric cancer in individuals with Li-Fraumeni syndrome</article-title>
          <source>Genet Med</source>
          <year>2011</year>
          <volume>14</volume>
          <fpage>651</fpage>
          <lpage>657</lpage>
          <pub-id pub-id-type="doi">10.1097/GIM.0b013e31821628b6</pub-id>
          <pub-id pub-id-type="pmid">21552135</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Chompret</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Brugieres</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Ronsin</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Gardes</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dessarps-Freichey</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Abel</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hua</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Ligot</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Dondon</surname>
            <given-names>MG</given-names>
          </name>
          <name>
            <surname>Bressac-de Paillerets</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Frebourg</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Lemerle</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Bonaiti-Pellie</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Feunteun</surname>
            <given-names>J</given-names>
          </name>
          <article-title>P53 germline mutations in childhood cancers and cancer risk for carrier individuals</article-title>
          <source>Br J Cancer</source>
          <year>2000</year>
          <volume>14</volume>
          <fpage>1932</fpage>
          <lpage>1937</lpage>
          <pub-id pub-id-type="pmid">10864200</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Villani</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Tabori</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Schiffman</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Shlien</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Beyene</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Druker</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Novokmet</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Finlay</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Malkin</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study</article-title>
          <source>Lancet Oncol</source>
          <year>2011</year>
          <volume>14</volume>
          <fpage>559</fpage>
          <lpage>567</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(11)70119-X</pub-id>
          <pub-id pub-id-type="pmid">21601526</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kaurah</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>MacMillan</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Boyd</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Senz</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>De Luca</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Chun</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Suriano</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Zaor</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Van Manen</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Gilpin</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Nikkel</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Connolly-Wilson</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Weissman</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rubinstein</surname>
            <given-names>WS</given-names>
          </name>
          <name>
            <surname>Sebold</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Greenstein</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Stroop</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Yim</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Panzini</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>McKinnon</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Greenblatt</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wirtzfeld</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Fontaine</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Coit</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Yoon</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chung</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Lauwers</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Pizzuti</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Vaccaro</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Redal</surname>
            <given-names>MA</given-names>
          </name>
          <etal/>
          <article-title>Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer</article-title>
          <source>JAMA</source>
          <year>2007</year>
          <volume>14</volume>
          <fpage>2360</fpage>
          <lpage>2372</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.297.21.2360</pub-id>
          <pub-id pub-id-type="pmid">17545690</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Couzin-Frankel</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Genome sequencing. Return of unexpected DNA results urged</article-title>
          <source>Science</source>
          <year>2013</year>
          <volume>14</volume>
          <fpage>1507</fpage>
          <lpage>1508</lpage>
          <pub-id pub-id-type="doi">10.1126/science.339.6127.1507</pub-id>
          <pub-id pub-id-type="pmid">23539571</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
